Understanding the costs of drug-related actions is an important aspect of the drug policy. Some of the funds allocated by governments for expenditure to tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, the majority of drug-related expenditure is not identified (‘unlabelled’) and must be estimated by modelling approaches.
In Italy, drug action plans do not have associated budgets. However, the methodology for estimating the social costs of drug use has been defined for some years and has provided an estimate of drug-related public expenditure between 2009 and 2012.
In 2012, drug-related public expenditure was estimated at approximately 0.18 % of gross domestic product (GDP), continuing the declining trend observed since 2010 (0.25 % of GDP in 2010 and 0.2 % of GDP in 2011). In 2012, the majority of total drug-related spending was for social care and healthcare.
In 2012, the social costs of drug use were estimated to represent 1 % of GDP, which was less than in 2011. Several reasons for the reduction have been suggested, such as reduced spending by drug users to purchase illicit substances and a decline in public expenditure on drugrelated initiatives.
Public expenditure related to illicit drugs in Italy
NB Based on estimates of Italy’s labelled and unlabelled public expenditure in 2012.